CEBP Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Risio, M.
Right arrow Articles by Rossini, F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Risio, M.
Right arrow Articles by Rossini, F. P.

Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 4 363-367, Copyright © 1993 by American Association for Cancer Research


ARTICLES

Bromodeoxyuridine uptake and proliferating cell nuclear antigen expression throughout the colorectal tumor sequence

M Risio, G Candelaresi and FP Rossini
Department of Pathology, Ospedale S. Giovanni Vecchio, Torino, Italy.

In vitro uptake of bromodeoxyuridine and expression of proliferating cell nuclear antigen (PCNA) were evaluated histochemically in rectal mucosa of control subjects and subjects with colorectal neoplasia in large intestine adenomas and adenocarcinomas. Both labeling indices progressively increased along the path of tumor progression, as did the difference between them (PCNA labeling indices were always greater than those of bromodeoxyuridine). The correlation between them was fairly close in the controls and in adenomas with low-grade dysplasia, whereas no significant linear relations were noted in adenomas with high-grade dysplasia or in adenocarcinomas. The progressive increase in PCNA would thus seem to be related to both hyperproliferation and neoplastic deregulation of PCNA synthesis. In the mucosa of subjects with colorectal neoplasia, PCNA labeling revealed hyperproliferation but not the surface-wards shift of the proliferative compartment detected by bromodeoxyuridine. PCNA expression, therefore, is not a sufficiently sensitive marker of the risk of tumor transformation in the intestinal mucosa.


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
R. S. Sandler, J. A. Baron, T. D. Tosteson, J. S. Mandel, and R. W. Haile
Rectal Mucosal Proliferation and Risk of Colorectal Adenomas: Results from a Randomized Controlled Trial
Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 653 - 656.
[Abstract] [Full Text]


Home page
GutHome page
S E Green, P Chapman, J Burn, A D Burt, M Bennett, D R Appleton, J S Varma, and J C Mathers
Colonic epithelial cell proliferation in hereditary non-polyposis colorectal cancer
Gut, July 1, 1998; 43(1): 85 - 92.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1993 by the American Association for Cancer Research.